Yoriko Harigaya1, Xiaojian Jiang2, Hongling Zhang2, Parthapratim Chandaroy2, Ethan M Stier2, Yuzhuo Pan2. 1. Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drug, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA. Yoriko.Harigaya@fda.hhs.gov. 2. Division of Bioequivalence II, Office of Bioequivalence, Office of Generic Drug, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.
Abstract
PURPOSE: To establish bioequivalence for topical ophthalmic corticosteroid suspensions, some of U.S. product-specific guidances (PSGs) for generic drug products recommend evaluation of aqueous humor (AH) pharmacokinetics (PK). However, the AH PK study is complex because the relationships among AH PK, subject demographics, ocular anatomy, physiology and the compounds' physicochemical characteristics are not well understood. The objective of this research is to provide an overview of the in vivo human AH studies submitted to the U.S. Food and Drug Administration (FDA) for ophthalmic corticosteroid suspensions and to investigate the impact of subject demographics on the human AH PK. METHODS: We summarized demographic data, sampling time points, sample size per time point and PK parameters to investigate correlations in the studies submitted to the FDA. RESULTS: In the evaluation of subject-specific covariates, the area under the concentration-time curves (AUC) and maximum concentrations (Cmax) were significantly different among ethnicities and age groups. Gender was not primarily associated with differences in AH PK. CONCLUSIONS: Our results suggest that the difference in ethnicity and age of the study population play an important role in the AH PK profiles of topical ophthalmic corticosteroid suspensions. Considering the subject-specific covariate effects in designing bioequivalence studies with AH PK endpoints could reduce bias from covariate imbalance and help identify true effects of formulation differences.
PURPOSE: To establish bioequivalence for topical ophthalmic corticosteroid suspensions, some of U.S. product-specific guidances (PSGs) for generic drug products recommend evaluation of aqueous humor (AH) pharmacokinetics (PK). However, the AH PK study is complex because the relationships among AH PK, subject demographics, ocular anatomy, physiology and the compounds' physicochemical characteristics are not well understood. The objective of this research is to provide an overview of the in vivo human AH studies submitted to the U.S. Food and Drug Administration (FDA) for ophthalmic corticosteroid suspensions and to investigate the impact of subject demographics on the human AH PK. METHODS: We summarized demographic data, sampling time points, sample size per time point and PK parameters to investigate correlations in the studies submitted to the FDA. RESULTS: In the evaluation of subject-specific covariates, the area under the concentration-time curves (AUC) and maximum concentrations (Cmax) were significantly different among ethnicities and age groups. Gender was not primarily associated with differences in AH PK. CONCLUSIONS: Our results suggest that the difference in ethnicity and age of the study population play an important role in the AH PK profiles of topical ophthalmic corticosteroid suspensions. Considering the subject-specific covariate effects in designing bioequivalence studies with AH PK endpoints could reduce bias from covariate imbalance and help identify true effects of formulation differences.
Authors: Edward B Moss; Yvonne M Buys; Stephanie A Low; Darana Yuen; Ya-Ping Jin; Kenneth R Chapman; Graham E Trope Journal: J Glaucoma Date: 2017-02 Impact factor: 2.503
Authors: Brita Roy; Carley Riley; Jeph Herrin; Erica S Spatz; Anita Arora; Kenneth P Kell; John Welsh; Elizabeth Y Rula; Harlan M Krumholz Journal: PLoS One Date: 2018-05-23 Impact factor: 3.240
Authors: Elisa Toropainen; Sara J Fraser-Miller; Dunja Novakovic; Eva M Del Amo; Kati-Sisko Vellonen; Marika Ruponen; Tapani Viitala; Ossi Korhonen; Seppo Auriola; Laura Hellinen; Mika Reinisalo; Unni Tengvall; Stephanie Choi; Mohammad Absar; Clare Strachan; Arto Urtti Journal: Pharmaceutics Date: 2021-03-26 Impact factor: 6.321
Authors: Maxime Le Merdy; Jessica Spires; Viera Lukacova; Ming-Liang Tan; Andrew Babiskin; Xiaoming Xu; Liang Zhao; Michael B Bolger Journal: Pharm Res Date: 2020-11-19 Impact factor: 4.200